
    
      The study is a 4-arm parallel design, randomized, double-blind, placebo-controlled,
      multicenter, dose-effect relationship, phase II clinical trial. The study is designed to
      assess efficacy and safety of 3 Doses of hepalatide in Combination with Pegylated Interferon
      Compared to Pegylated Interferon Alone in patients with Chronic Hepatitis B .Subjects will be
      randomly assigned to the 2.1mg, 4.2mg, and 6.3mg dose groups , 32 subjects in each group .
      The subjects in each dose group will be randomly and double-blindly administered the
      corresponding dose of trial drug or placebo in a ratio of 3:1. The subjects in each dose
      group who received placebo treatment combine as the placebo group. All subjects will receive
      Pegylated Interferon treatment for 28 weeks as the basic treatment,trial drug or placebo
      treatment for 24 weeks continuously , followed by a safety follow-up for 4 weeks.
    
  